comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 23:31:38 - browse：9

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

entertainment

WSS

Celiac disease study examines precisely how gluten triggers injury

Alabama frozen embryo ruling has major implications for IVF clinics

Can CDC director Mandy Cohen drive consensus in Washington?

Medicare inequities exacerbate Puerto Rico’s health disparities

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Can CDC director Mandy Cohen drive consensus in Washington?

hotspot

comprehensive

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Who gets to use the title 'doctor'?

New air purifier tech could be key to improving indoor air quality

Can CDC director Mandy Cohen drive consensus in Washington?

Alkermes shareholders re

Blood tests recalled over risk of missed heart attack diagnosis

Continuity nursing helped my family in our darkest PICU moments

PBM reform efforts get punted in Congress

Tori Bowie and the unacceptable rates of Black maternal death

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

knowledge

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Congress: Eradicate hepatitis C and reduce the deficit

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Why police arrested suspected Gilgo Beach killer away from his house

entertainment

leisure time

entertainment

Wikipedia